Paysign Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Paysign şirketinin toplam hissedar öz sermayesi $28.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $167.0M ve $138.5M dir. Paysign 'in FAVÖK'ü $896.7K faiz karşılama oranı -0.3 dur. Şirketin $10.3M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-0.3x
Nakit	US$10.29m
Eşitlik	US$28.51m
Toplam yükümlülükler	US$138.47m
Toplam varlıklar	US$166.97m

Son finansal sağlık güncellemeleri

Recent updates

Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?

Sep 07

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02

Paysign: Expect Rapid Growth In Its Pharma Business

Jun 30

Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Apr 26

Earnings Update: Here's Why Analysts Just Lifted Their PaySign, Inc. (NASDAQ:PAYS) Price Target To US$3.75

Aug 13

Calculating The Fair Value Of PaySign, Inc. (NASDAQ:PAYS)

Jun 14

At US$1.42, Is PaySign, Inc. (NASDAQ:PAYS) Worth Looking At Closely?

May 16

PaySign: A 'Backdoor' $2 Stagflation Play

Mar 29

Paysign: My Top Rebound Pick For 2022

Dec 28

Paysign: The Plasma Toll Booth

Sep 23

PaySign's Post-Pandemic Payoff

Sep 07

Why PaySign Is A Very Good Company

Dec 28

PaySign: Long-Term Story Still Intact

Dec 21

Paysign reports Q3 results

Nov 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PAYS 'nin kısa vadeli varlıkları ( $147.5M ) kısa vadeli yükümlülüklerini ( $135.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: PAYS şirketinin kısa vadeli varlıkları ( $147.5M ) uzun vadeli yükümlülüklerini ( $2.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PAYS borçsuzdur.

Borcun Azaltılması: PAYS un 5 yıl önce borcu yoktu.

Borç Kapsamı: PAYS un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: PAYS şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Paysign Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

PaySign, Inc. announced delayed 10-Q filing

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Paysign, Inc. Reiterates Earnings Guidance for the Year 2024

Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?

New minor risk - Insider selling

Consensus EPS estimates fall by 22%, revenue upgraded

Price target increased by 7.5% to US$6.58

Paysign, Inc. Revises Earnings Guidance for the Full Year 2024

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Paysign, Inc. Revises Earnings Guidance for the Full Year 2024

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improves as stock rises 34%

Paysign: Expect Rapid Growth In Its Pharma Business

Independent Director exercised options to buy US$85k worth of stock.

Consensus EPS estimates increase by 33%

Price target increased by 8.9% to US$6.13

First quarter 2024 earnings released: EPS: US$0.006 (vs US$0.003 loss in 1Q 2023)

Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

New minor risk - Share price stability

Investor sentiment improves as stock rises 26%

Consensus EPS estimates fall by 30%, revenue upgraded

PaySign, Inc., Annual General Meeting, May 03, 2024

Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching

Price target increased by 14% to US$5.25

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CFO & Treasurer exercised options and sold US$79k worth of stock

PaySign, Inc. Announces Executive Changes

Revenues Tell The Story For PaySign, Inc. (NASDAQ:PAYS)

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of the Common Stock of Paysign, Inc

Consensus EPS estimates increase by 25%

New major risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Market cap size

Consensus EPS estimates fall by 50%

PaySign, Inc. Reaffirms Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0.004 loss in 2Q 2022)

Co-Founder exercised options and sold US$71k worth of stock

New minor risk - Market cap size

Consensus EPS estimates fall by 20%

First quarter 2023 earnings released: US$0.003 loss per share (vs US$0.006 loss in 1Q 2022)

Consensus EPS estimates increase by 36%

Price target increased by 13% to US$4.31

CFO & Treasurer recently sold US$101k worth of stock

PaySign, Inc. Elects Jeffrey B. Newman to Its Board of Directors

Consensus EPS estimates have been upgraded.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

PaySign, Inc. Provides Earnings Guidance for the Fiscal Year 2022

General Counsel exercised options to buy US$54k worth of stock.

The Recovery At PaySign Has Legs

Earnings Update: Here's Why Analysts Just Lifted Their PaySign, Inc. (NASDAQ:PAYS) Price Target To US$3.75

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$3.75

PaySign, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2022

Calculating The Fair Value Of PaySign, Inc. (NASDAQ:PAYS)

At US$1.42, Is PaySign, Inc. (NASDAQ:PAYS) Worth Looking At Closely?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

PaySign, Inc. Provides Earnings Guidance for the Full Year of 2022

PaySign, Inc. Provides Earnings Guidance for the Full Year of 2022

Price target decreased to US$3.44

Insufficient new directors

Price target decreased to US$3.44

Insufficient new directors

PaySign: A 'Backdoor' $2 Stagflation Play

Paysign: My Top Rebound Pick For 2022

Paysign: The Plasma Toll Booth

PaySign's Post-Pandemic Payoff

PaySign, Inc.(NasdaqCM:PAYS) dropped from Russell 2000 Defensive Index

PaySign, Inc. Provides Earnings Guidance for the Full Year 2021

Paysign, Inc. Announces Retirement of Joan M. Herman, as Chief Operating Officer

Why PaySign Is A Very Good Company

PaySign: Long-Term Story Still Intact

PaySign, Inc. and ImmunoTek Bio Centers LLC Collaborate in Support of COVID-19 Convalescent Plasma Collection

PaySign, Inc. announced delayed 10-Q filing

Paysign reports Q3 results

PaySign, Inc. to Report Q3, 2020 Results on Nov 17, 2020